- ThermoGenesis (KOOL) Q3/13 Results – HOLD – Based On Capacities, Capabilities, Revenue, Competition And Trials – Otherwise KOOL Will “drip” Downward As 2013 “floats”!
- NeoStem (NYSE MKT: NBS) Multiple Geography IP Patents
- Athersys (ATHX) Q1/13 Results – SELL Until It Settles And Then Re-enter!
- Aastrom (ASTM) Notice Of Delisting
- BioTime's (NYSE MKT: BTX) Subsidiary Awarded $1.5 M R&D Grant
Henry McCusker
ABOUT
Analyst, Journalist and Publisher ... Henry enters his tenth (10) year at Scimitar Equity -Regenerative Medicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and high-impact synthesis. He was VP - Strategic Planning and Communication at Curis (2001-2002), HQCM focusing on healthcare investments (NYSE:HQH/HQL) from (1985-2001)and founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA. Past experiences include Thermo Scientific, SWEC following 5 years at the FBI. A former military officer, Henry has been an adjunct professor at ...More
SNAPSHOT
- Description: Independent / boutique research firm analyst. Trading frequency: Weekly
- Interests: Stocks - long, Stocks - short
COMPANY
Scimitar Equity-Regenerative Medicine Investors Scimitar Equity's mission is to provide investors with real-time actionable intelligence to define the short, near and long term catalysts.
BLOG
Scimitar Equity Blog
I started this commentary to update news flow and insightful opinions. Wall Street has dramatically slashed its ranks of analysts providing research but, scientific platforms and industry sectors need to be better researched for conviction ideas.
Book
Currently, there are no book details for Henry McCusker.
LATEST STOCKTALK
more »
ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
Nov 30, 2011
Latest Comments
more »
Latest comments on Henry's Articles
LATEST ARTICLES & INSTAPOSTS
more »